Entera Bio to Present at 2022 Maxim Virtual Growth Conference
March 22, 2022 08:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company...
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
March 08, 2022 06:30 ET
|
Entera Bio Ltd.
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more...
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
March 03, 2022 09:50 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Xtant Medical to Issue Third Quarter 2018 Results on November 14, 2018
November 12, 2018 09:30 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, MT, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...